Methods and corresponding catalysts are provided for conversion of an aromatics feed containing C.sub.8+ aromatics, particularly C.sub.9+ aromatics, to form a converted product mixture comprising, e.g., benzene and/or xylenes. The aromatic feed can be converted in the presence of a catalyst that includes a mixture of a first zeolite having an MEL framework, such as ZSM-11, and a second zeolite having a MOR framework, such as mordenite, particularly a mordenite synthesized using TEA or MTEA as a structure directing agent. The weight ratio of the first zeolite to the second zeolite in the catalyst can be from 0.3 to 1.2, or from 0.3 to 1.1, or from 0.3 to 1.0. The catalyst can further include one or more metals supported on the catalyst, such as a combination of metals.

A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.

Methods for interconverting olefins in an olefin-rich hydrocarbon stream include contacting the olefin-rich hydrocarbon stream with a catalyst system in an olefin interconversion unit to produce an interconverted effluent comprising ethylene and propylene. The contacting may be conducted at a reaction temperature from 450° C. to 750° C., a reaction pressure from 1 bar to 5 bar, and a residence time from 0.5 seconds to 1000 seconds. The catalyst system includes a framework-substituted beta zeolite. The framework-substituted beta zeolite has a *BEA aluminosilicate framework that has been modified by substituting a portion of framework aluminum atoms of the *BEA aluminosilicate framework with beta-zeolite Al-substitution atoms independently selected from the group consisting of titanium atoms, zirconium atoms, hafnium atoms, and combinations thereof.

A catalyst composition comprising (a) carrier comprising (i) 5 to 95 wt % mordenite type zeolite having a mean crystallite length parallel to the direction of the 12-ring channels of 60 nm or less and a mesopore volume of at least 0.10 cc/gram, (ii) 5 to 95 wt % ZSM-5 type zeolite; and (iii) 10 to 60 wt % inorganic binder; and (b) 0.001 to 10 wt % of one or more catalytically active metals, wherein the inorganic binder comprises titania, its preparation and its use in alkylaromatic conversion.

Methods use a catalytic composition built up from a ceramic material including a catalytic material and a first inorganic binder and a second inorganic binder and a catalytic structure made thereof. Preferably, the structure is made by a colloidal ceramic shaping technique. The structure is used for catalytic or ion exchange applications. The catalytic structures have excellent mechanical, physicochemical and catalytic properties.

A disproportionation and transalkylation catalyst can be used in the catalytic conversion of alkyl aromatic hydrocarbons. The catalyst contains an acidic molecular sieve, a first metal component immobilized on the acidic molecular sieve and an oxide additive. The first metal contained in the first metal component is at least one selected from the group of Group VB metals, Group VIB metals and Group VIIB metals, the catalyst has a mediate strong acid content of 0.05-2.0 mmol/g of catalyst, and a ratio of the mediate strong acid content to the total acid content of 60-99%. When used in the catalytic conversion of alkyl aromatic hydrocarbons, the catalyst exhibits high reaction activity, low aromatic hydrocarbon loss rate.

A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.

A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.

A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.

A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.